Blood test to watch for liver cancer return
Part of Cancer, Digestive system clinical trials.
This trial studies a new blood test that looks for DNA from cancer cells' mitochondria to see if it can catch liver cancer coming back earlier. The goal is to help doctors find recurrence faster and improve follow-up care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cancer (hepatocellular carcinoma).
- Your diagnosis follows standard guidelines from liver disease experts.
- You have at least one tumor that can be measured on a scan.
- Your doctor expects you to live for 12 weeks or more.
- You are willing to sign a consent form and follow the study plan.
- You do not have other active cancers or serious medical problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new gene test (GNB4 and Riplet) to monitor liver cancer patients for possible return of cancer after treatment. It is designed for people who have liver cancer and are having surgery, transplant, ablation, or TACE treatment.
This study is looking for people with or without liver cancer to test a new way to find liver cancer early using blood or tissue samples. It aims to help catch the disease sooner.
This study looks at special blood markers in people with liver cancer (hepatocellular carcinoma) who are about to have a procedure called TACE. The goal is to see if these markers can help predict how well the treatment works. You may be able to join if you are getting TACE as part of your standard care.
This trial studies a new blood test that looks for bits of tumor DNA (ct-mtDNA) to see if it can detect if biliary tract cancer has come back earlier than standard scans. The test might help doctors monitor for recurrence more closely.
This trial uses a blood test to check for signs of liver cancer coming back after treatment. It may help find recurrence earlier than standard scans.
This study checks whether a blood test (circulating tumor DNA) can help predict if hepatocellular carcinoma (HCC) will return after curative treatment like surgery or ablation. If it works, it may help doctors plan closer follow-up or earlier treatment if recurrence risk is higher.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.